{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:42:39Z","timestamp":1792154559725,"version":"4.4.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T00:00:00Z","timestamp":1560124800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T00:00:00Z","timestamp":1560124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s40272-019-00341-x","type":"journal-article","created":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T03:57:28Z","timestamp":1560139048000},"page":"283-290","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Purified Cannabidiol for Treatment of Refractory Epilepsies in Pediatric Patients with Developmental and Epileptic Encephalopathy"],"prefix":"10.1007","volume":"21","author":[{"given":"Nicola","family":"Pietrafusa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Ferretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Trivisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"de Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costanza","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusy","family":"Carf\u00ec Pavia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Tondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Cappelletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Vigevano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8120-0287","authenticated-orcid":false,"given":"Nicola","family":"Specchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,10]]},"reference":[{"issue":"4","key":"341_CR1","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/epi.13709","volume":"58","author":"IE Scheffer","year":"2017","unstructured":"Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology. Epilepsia. 2017;58(4):512\u201321.","journal-title":"Epilepsia."},{"issue":"3","key":"341_CR2","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S1474-4422(15)00250-1","volume":"15","author":"A McTague","year":"2016","unstructured":"McTague A, Howell KB, Cross JH, Kurian MA, Scheffer IE. The genetic landscape of the epileptic encephalopathies of infancy and childhood. Lancet Neurol. 2016;15(3):304\u201316.","journal-title":"Lancet Neurol."},{"issue":"1","key":"341_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/088307389200700102","volume":"7","author":"JF Donat","year":"1992","unstructured":"Donat JF. The age-dependent epileptic encephalopathies. J Child Neurol. 1992;7(1):7\u201321.","journal-title":"J Child Neurol."},{"issue":"13","key":"341_CR4","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1212\/WNL.0b013e31826c1b55","volume":"79","author":"AT Berg","year":"2012","unstructured":"Berg AT, Zelko FA, Levy SR, Testa FM. Age at onset of epilepsy, pharmacoresistance, and cognitive outcomes: a prospective cohort study. Neurology. 2012;79(13):1384\u201391.","journal-title":"Neurology."},{"issue":"2","key":"341_CR5","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1124\/jpet.109.159145","volume":"332","author":"NA Jones","year":"2010","unstructured":"Jones NA, Hill AJ, Smith I, Bevan SA, Williams CM, Whalley BJ, et al. Cannabidiol displays. Antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther. 2010;332(2):569\u201377.","journal-title":"J Pharmacol Exp Ther."},{"issue":"5","key":"341_CR6","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.seizure.2012.03.001","volume":"21","author":"NA Jones","year":"2012","unstructured":"Jones NA, Glyn SE, Akiyama S, Hill TD, Hill AJ, Weston SE, et al. Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure. 2012;21(5):344\u201352.","journal-title":"Seizure."},{"issue":"3","key":"341_CR7","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","volume":"15","author":"O Devinsky","year":"2016","unstructured":"Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15(3):270\u20138.","journal-title":"Lancet Neurol."},{"issue":"10","key":"341_CR8","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1111\/epi.13499","volume":"57","author":"EJ Hess","year":"2016","unstructured":"Hess EJ, Moody KA, Geffrey AL, Pollack SF, Skirvin LA, Bruno PL, et al. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Epilepsia. 2016;57(10):1617\u201324.","journal-title":"Epilepsia."},{"issue":"1","key":"341_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1177\/0883073816669450","volume":"32","author":"JS Gofshteyn","year":"2017","unstructured":"Gofshteyn JS, Wilfong A, Devinsky O, Bluvstein J, Charuta J, Ciliberto MA, et al. Cannabidiol as a potential treatment for febrile infection-related epilepsy syndrome (FIRES) in the acute and chronic phases. J Child Neurol. 2017;32(1):35\u201340.","journal-title":"J Child Neurol."},{"key":"341_CR10","unstructured":"GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences announce FDA approval of EPIDIOLEX\u00ae (cannabidiol) oral solution\u2014the first plant-derived cannabinoid prescription medicine. \nhttps:\/\/www.gwpharm.com\/about-us\/news\/gw-pharmaceuticals-plc-and-its-us-subsidiary-greenwich-biosciences-announce-fda\n\n. Accessed 15 Nov 2018."},{"issue":"20","key":"341_CR11","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","volume":"378","author":"O Devinsky","year":"2018","unstructured":"Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome Neurology. N Engl J Med. 2018;378(20):1888\u201397.","journal-title":"N Engl J Med."},{"issue":"10125","key":"341_CR12","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","volume":"391","author":"EA Thiele","year":"2018","unstructured":"Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, et al. CBD in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085\u201396.","journal-title":"Lancet."},{"issue":"21","key":"341_CR13","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","volume":"376","author":"O Devinsky","year":"2017","unstructured":"Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, et al. Cannabidiol in Dravet syndrome study group. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(21):2011\u201320.","journal-title":"N Engl J Med."},{"key":"341_CR14","unstructured":"FDA. 2018. \nhttps:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm611046.htm\n\n. Accessed 15 Dec 2018."},{"key":"341_CR15","unstructured":"GW Pharmaceuticals announces the European Medicines Agency (EMA) accepts Epidiolex\u00ae (cannabidiol) Marketing Authorization Application (MAA) for review. \nhttps:\/\/globenewswire.com\/news-release\/2018\/02\/05\/1333218\/0\/en\/GW-Pharmaceuticals-Announces-the-European-Medicines-Agency-EMA-Accepts-Epidiolex-Cannabidiol-Marketing-Authorization-Application-MAA-for-Review.html\n\n. Accessed 1 Nov 2018."},{"key":"341_CR16","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jpba.2016.05.033","volume":"128","author":"C Citti","year":"2016","unstructured":"Citti C, Ciccarella G, Braghiroli D, Parenti C, Vandelli MA, Cannazza G. Medicinal cannabis: Principal cannabinoids concentration and their stability evaluated by a high performance liquid chromatography coupled to diode array and quadrupole time of flight mass spectrometry method. J Pharm Biomed Anal. 2016;128:201\u20139.","journal-title":"J Pharm Biomed Anal."},{"issue":"10","key":"341_CR17","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1515\/cclm-2016-1060","volume":"55","author":"R Pacifici","year":"2017","unstructured":"Pacifici R, Marchei E, Salvatore F, Guandalini L, Busard\u00f2 FP, Pichini S. Evaluation of cannabinoids concentration and stability in standardized preparations of cannabis tea and cannabis oil by ultra-high performance liquid chromatography tandem mass spectrometry. Clin Chem Lab Med. 2017;55(10):1555\u201363.","journal-title":"Clin Chem Lab Med."},{"key":"341_CR18","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jpba.2017.11.073","volume":"150","author":"L Calvi","year":"2018","unstructured":"Calvi L, Pentimalli D, Panseri S, Giupponi L, Gelmini F, Beretta G, Vitali D. Comprehensive quality evaluation of medical Cannabis sativa L. inflorescence and macerated oils based on HS-SPME coupled to GC\u2013MS and LC\u2013HRMS (q-exactive orbitrap\u00ae) approach. J Pharm Biomed Anal. 2018;150:208\u201319.","journal-title":"J Pharm Biomed Anal."},{"issue":"1","key":"341_CR19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/jphp.12845","volume":"70","author":"C Carcieri","year":"2018","unstructured":"Carcieri C, Tomasello C, Simiele M, De Nicol\u00f2 A, Avataneo V, Canzoneri L. Cannabinoids concentration variability in cannabis olive oil galenic preparations. J Pharm Pharmacol. 2018;70(1):143\u20139.","journal-title":"J Pharm Pharmacol."},{"key":"341_CR20","unstructured":"Decreto 9 novembre 2015: Funzioni di Organismo statale per la cannabis previsto dagli articoli 23 e 28 della convenzione unica sugli stupefacenti del 1961, come modificata nel 1972. Available online: Molecules 2018, 23, 1230 21 of 22. \nhttp:\/\/www.gazzettaufficiale.it\/eli\/id\/2015\/11\/30\/15A08888\/sg;jsessionid=p1rnwNujUKlqQ5azhA%20Q95A__.ntc-as3-guri2\n\n. Accessed 1 Oct 2018."},{"key":"341_CR21","doi-asserted-by":"publisher","first-page":"759","DOI":"10.3389\/fneur.2018.00759","volume":"9","author":"FA Pamplona","year":"2018","unstructured":"Pamplona FA, da Silva LR, Coan AC. Potential clinical benefits of CBD-rich cannabis extracts over purified CBD in treatment-resistant epilepsy: observational data meta-analysis. Front Neurol. 2018;9:759.","journal-title":"Front Neurol."},{"key":"341_CR22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.yebeh.2018.02.009","volume":"81","author":"D Neubauer","year":"2018","unstructured":"Neubauer D, Perkovi\u0107 Benedik M, Osredkar D. Cannabidiol for treatment of refractory childhood epilepsies: experience from a single tertiary epilepsy center in Slovenia. Epilepsy Behav. 2018;81:79\u201385.","journal-title":"Epilepsy Behav."},{"key":"341_CR23","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.yebeh.2018.01.026","volume":"80","author":"GS Porcari","year":"2018","unstructured":"Porcari GS, Fu C, Doll ED, Carter EG, Carson RP. Efficacy of artisanal preparations of Cannabidiol for the treatment of epilepsy: practical experiences in a tertiary medical center. Epilepsy Behav. 2018;80:240\u20136.","journal-title":"Epilepsy Behav."},{"key":"341_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/molecules23051230","volume":"23","author":"R Pavlovic","year":"2018","unstructured":"Pavlovic R, Nenna G, Calvi L, Panseri S, Borgonovo G, Giupponi L, et al. Quality traits of \u201cCBD oils\u201d: cannabinoids content, terpene fingerprint and oxidation stability of European commercially available preparations. Molecules. 2018;23:5.","journal-title":"Molecules."},{"key":"341_CR25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.seizure.2016.01.004","volume":"35","author":"M Tzadok","year":"2016","unstructured":"Tzadok M, Uliel-Siboni S, Linder I, Kramer U, Epstein O, Menascu S, et al. CBD-enriched medical cannabis for intractable pediatric epilepsy: the current Israeli experience. Seizure. 2016;35:41\u20134.","journal-title":"Seizure."},{"issue":"7","key":"341_CR26","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.braindev.2018.03.013","volume":"40","author":"M Hausman-Kedem","year":"2018","unstructured":"Hausman-Kedem M, Menascu S, Kramer U. Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents\u2014an observational, longitudinal study. Brain Dev. 2018;40(7):544\u201351.","journal-title":"Brain Dev."},{"issue":"3","key":"341_CR27","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.yebeh.2013.08.037","volume":"29","author":"BE Porter","year":"2013","unstructured":"Porter BE, Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav. 2013;29(3):574\u20137.","journal-title":"Epilepsy Behav."},{"issue":"7","key":"341_CR28","first-page":"S87","volume":"35","author":"L Fusco","year":"1994","unstructured":"Fusco L, Vigevano F. Tonic spasm seizures: a particular and previously unreported type of seizure. Epilepsia. 1994;35(7):S87.","journal-title":"Epilepsia"},{"key":"341_CR29","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.yebeh.2015.04.009","volume":"47","author":"SA Hussain","year":"2015","unstructured":"Hussain SA, Zhou R, Jacobson C, Weng J, Cheng E, Lay J. Perceived efficacy of cannabidiol-enriched cannabis extracts for treatment of pediatric epilepsy: a potential role for infantile spasms and Lennox-Gastaut syndrome. Epilepsy Behav. 2015;47:138\u201341.","journal-title":"Epilepsy Behav."},{"key":"341_CR30","unstructured":"Trial of cannabidiol (CBD; GWP42003-P) for infantile spasms (GWPCARE7). \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT02953548\n\n. Accessed on 1 Jan 2018."},{"issue":"1","key":"341_CR31","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s13181-016-0552-x","volume":"13","author":"GS Wang","year":"2017","unstructured":"Wang GS. Pediatric concerns due to expanded cannabis use: unintended consequences of legalization. J Med Toxicol. 2017;13(1):99\u2013105.","journal-title":"J Med Toxicol."},{"issue":"8","key":"341_CR32","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/epi.13815","volume":"58","author":"EC Rosenberg","year":"2017","unstructured":"Rosenberg EC, Louik J, Conway E, Devinsky O, Friedman D. Quality of life in childhood epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with CBD. Epilepsia. 2017;58(8):96\u2013100.","journal-title":"Epilepsia."},{"issue":"8","key":"341_CR33","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/epi.13060","volume":"56","author":"AL Geffrey","year":"2015","unstructured":"Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56(8):1246\u201351.","journal-title":"Epilepsia"},{"issue":"11","key":"341_CR34","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s40263-018-0578-5","volume":"32","author":"L Taylor","year":"2018","unstructured":"Taylor L, Gidal B, Blakey G, Tayo B, Morrison G. A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects. CNS Drugs. 2018;32(11):1053\u201367.","journal-title":"CNS Drugs."},{"issue":"Suppl 4","key":"341_CR35","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/epi.12732","volume":"55","author":"GD Montouris","year":"2014","unstructured":"Montouris GD, Wheless JW, Glauser TA. The efficacy and tolerability of pharmacologic treatment options for Lennox-Gastaut syndrome. Epilepsia. 2014;55(Suppl 4):10\u201320.","journal-title":"Epilepsia."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-019-00341-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40272-019-00341-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-019-00341-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T23:30:18Z","timestamp":1591659018000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40272-019-00341-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,10]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["341"],"URL":"https:\/\/doi.org\/10.1007\/s40272-019-00341-x","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,10]]},"assertion":[{"value":"10 June 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was not funded.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Nicola Pietrafusa, Alessandro Ferretti, Marina Trivisano, Luca de Palma, Costanza Calabrese, Giusy Carfi\u2019 Pavia, Ilaria Tondo, Simona Cappelletti, Federico Vigevano, and Nicola Specchio have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This trial was conducted in accordance with International Conference on Harmonization Good Clinical Practice guidelines and ethical principles that have their origin in the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Written informed consent was obtained from each patient\u2019s parent or primary caregiver before any trial-related procedures were performed.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}